Oncology

Anal cancer

  • Budget impact models in anal cancer
  • Cost calculator to reflect change in patient estimation approach in anal cancer

Bladder cancer

  • Burden of disease deck in bladder cancer
  • Payer value deck in bladder cancer
  • Frequently asked questions in bladder cancer
  • Payer implementation guide in bladder cancer
  • Burden of disease deck, payer value dossier deck and frequently asked questions deck in 2nd line bladder cancer
  • Burden of disease deck in non-muscle invasive bladder cancer
  • Payer value deck update in 2nd line bladder cancer
  • Standardization of economic models in bladder cancer
  • Qualitative research in bladder cancer
  • Clinical trial analyses to support health-related quality of life in bladder cancer
  • ‘Fit for purpose’ tools review in bladder cancer
  • Development of a new PRO measure in bladder cancer
  • AMNOG analyses to support health-related quality of life in bladder cancer

Brain metastases

  • Development and validation of a PRO measure in brain metastases
  • Development and validation of a questionnaire to assess brain metastases
  • Linguistic validation of a brain metastases assessment

Brain tumours

  • Health Economics and Translational Advisory Board on paediatric brain tumours
  • Support in personalised medicine health economics on brain tumours

Breast cancer

  • Global value dossier for treatment in breast cancer
  • Data collection of costs associated with breast cancer care
  • Manuscript on the German model for a hormonal drug used in the treatment of breast cancer
  • Development of two budget impact models in breast cancer with population data by city
  • Two budget impact models for Italy for an injectable chemotherapy drug for breast cancer
  • Budget impact model in breast cancer for France
  • Development of a cost-calculator for a biosimilar for breast cancer
  • Payer value deck in breast cancer
  • Payer value deck update for a breast cancer biosimilar
  • Burden of disease deck in breast cancer
  • Response to payer questions in breast cancer
  • Response to payer questions update for a breast cancer biosimilar
  • Burden of disease deck and frequently asked questions deck in breast cancer biosimilars
  • One-pager communication in a breast cancer biosimilar
  • Productivity and QoL study in breast cancer
  • Literature review and consultancy on breast cancer
  • e-v@luate platforms in breast cancer
  • Market access training and workshop on breast cancer
  • Primary research of fixed dose combinations pricing in breast cancer

HER2 positive breast cancer

  • Literature review of productivity data in HER2 positive breast cancer
  • Budget impact model for a biosimilar in HER2 breast cancer

Advanced breast cancer

  • Development of a perceived tolerability questionnaire in first line treatment of advanced breast cancer
  • Strategy for an injectable chemotherapy drug for advanced breast cancer and submission to NICE/SMC
  • Budget impact model and analysis for an injectable chemotherapy drug for advanced breast cancer in 5 EU countries
  • Economic evaluation of a therapy for postmenopausal women with advanced breast cancer (with the perspective of 3rd party national and local payers in the UK)
  • Development and population of an economic model in advanced breast cancer
  • Conference poster on a cost utility analysis of two treatments for advanced breast cancer
  • Conference poster on the economic evaluation of a therapy for postmenopausal women with advanced breast cancer
  • Phase IV non-interventional prospective observational study comparing patient reported outcomes in advanced breast cancer
  • PRO label review manuscript development in advanced/metastatic breast cancer

Metastatic breast cancer

  • Value dossier and e-v@luate platform in metastatic breast cancer
  • Scientific communication of cost-effectiveness analysis in metastatic breast cancer
  • PRO knowledge base instruments and methods library for metastatic breast cancer
  • Update to a Health Impact Projection (HIP) model in metastatic triple negative breast cancer

Triple negative breast cancer

  • Global value dossier and upload to e-v@luate platform in triple negative breast cancer
  • Data analyses on a multi-indication budget impact model and cost utility model in triple negative breast cancer
  • Payer value tool in triple negative breast cancer (TNBC)
  • Standalone budget impact models in triple negative breast cancer
  • Update to a Health Impact Projection (HIP) model in neo-adjuvant triple negative breast cancer

Cancer-related pain, fatigue and side effects

Cancer-related pain and fatigue

  • Initial consultation to design a study in order to generate health utilities values associated with different levels of cancer-related pain
  • Utility study in breakthrough cancer pain
  • Update of report for utility elicitation in breakthrough cancer pain
  • Abstract, manuscript and budget impact model on breakthrough cancer pain
  • Training in pilot budget impact model for a treatment for patients with breakthrough cancer pain
  • SMC submission in breakthrough cancer pain
  • Development of a breakthrough cancer pain submission to the All Wales Medicines Strategy Group (AWMSG)
  • Attendance at an AWMSG meeting with regards to strategic consultancy in breakthrough cancer pain
  • Expert interviews and amendment project to heath economic model for a treatment for breakthrough cancer pain
  • Economic evaluation of a treatment for breakthrough cancer pain in Canada
  • Budget impact tool for a treatment for patients with breakthrough cancer pain in the UK
  • Consulting support and development of a briefing document to support fatigue symptom claims in cancer pain
  • Recommendation of a measure of chronic cancer pain
  • Assessment of a pain communication tool for advanced cancer patients: a cross-sectional survey
  • Qualitative research for the Cancer-Related Fatigue Consortium
  • Phase II cognitive interviews on Patient-Reported Outcomes of Fatigue – Cancer (PROOF-C)
  • Cancer-related fatigue consortium: qualitative research in the experience of fatigue among cancer patients
  • Qualitative research on the experience of fatigue among cancer patients
  • PRO development, abstracts and posters on cancer-related fatigue

Cancer-related anaemia

  • Linking a cost utility assessment model with a budget impact model for treatment for anaemia in cancer
  • NICE consultancy for a treatment for chemotherapy-induced anaemia
  • Statistical pharmacoeconomic analysis of patient level data for a treatment for anaemia following chemotherapy
  • Phase II cognitive interviews and regulatory support in inflammatory anaemia in cancer
  • Evaluation of the PRO landscape using a systematic literature review on chemo-induced anaemia in oncology

Other cancer-related side effects

  • Value dossier on a drug used to treat febrile neutropenia
  • Plan, execute and follow up a Train-the-Trainer meeting on chemotherapy-induced febrile neutropenia
  • Development of a PRO measure in muscle wasting (cancer cachexia) in prostate cancer, sarcopenia, gastric cancer and colorectal cancer
  • Debriefing of the cancer associated fibroblasts (CaF) PRO
  • SMC re-submission and economic analysis for a treatment for anthracycline extravasation
  • Case control study of costs associated with a treatment for oral mucositis in transplant patients
  • Literature review and recommendations on PROs for peripheral neuropathy due to chemotherapy in cancer patients
  • Review of PRO instruments for use in uveal melanoma and biliary tract cancer

Cervical cancer

  • Budget impact model in cervical cancer
  • Manuscript on cervical cancer
  • Literature review on cervical cancer
  • Development of a PRO strategy in cervical cancer and HPV
  • Summary report, top-up literature review, meta-analysis, editorial board and manuscripts on HPV infection and cervical cancer

Colorectal cancer

  • Adaptation of a multi-indication value-based pricing model in colorectal cancer in China
  • Project management of a mixed treatment analysis on colorectal cancer
  • Update to a payer value slide deck in metastatic colorectal cancer
  • Value-based model in colorectal cancer
  • Payer communications strategy and tools in colorectal cancer
  • Reimbursement dossiers in subgroups of colorectal cancer
  • Mini literature review in metastatic colorectal cancer
  • Literature review and payer communication tools in metastatic colorectal cancer
  • Translation to support development of a value dossier and budget impact model in capsule endoscopy for colonoscopy
  • Global model update and country adaptations for a multi-indication value-based pricing (VBP) model on colorectal cancer
  • Update to a Belgian value-based pricing model in colorectal cancer
  • Reimbursement scenario analysis in oncology for 11 country adaptations and inclusion of colorectal cancer
  • Structured literature review in metastatic colorectal cancer
  • Communication tool to support a budget impact model in metastatic colorectal cancer
  • Development of one-pager briefing documents on metastatic colorectal cancer
  • PRO assessment on the neurotoxicity of a treatment for advanced colorectal cancer
  • Clinical trial analyses to support HRQoL in recurrent and metastatic microsatellite instability high colorectal cancer
  • White Paper on continuous infusion in colorectal cancer
  • Development of cost arguments and brochure development in colorectal cancer
  • Network meta-analysis on the efficacy of treatment for metastatic colorectal cancer
  • Recommendations on the economic impact of a treatment for metastatic colorectal cancer
  • Network meta-analysis of a treatment versus other biologics for metastatic colorectal cancer in 1st line, 2nd line and multiple line settings
  • Web-based survey to understand patient-preference and satisfaction in advanced colorectal cancer

Esophogeal cancer

  • Payer value deck in esophogeal cancer
  • Burden of disease deck in esophogeal cancer
  • Response to payer questions in esophogeal cancer
  • Clinical trial analyses to support HRQoL in oesophageal cancer
  • Reimbursement scenario analysis in oncology for 11 country adaptations and inclusion of esophageal cancers

Gastric cancer

  • Global value dossier for treatment in gastric cancer
  • Development of a cost-calculator for a biosimilar for gastric cancer
  • Review of a SMC submission for a chemotherapy drug for advanced gastric cancer
  • Burden of disease deck, payer value dossier deck and frequently asked questions deck in gastric cancer
  • Payer value deck in 1st line gastric cancer
  • Response to payer questions in 1st line gastric cancer
  • Literature and PRO strategy for gastric oesophageal cancer
  • Literature review and development of a PRO strategy for gastric cancer
  • Statistical analyses to support HRQoL in gastric cancer, and estimation of EQ-5D utilities for an Asian population in a trial based on existing data and non-Asian trial utility data
  • Advisory board attendance and presentation for utilities in gastric cancer and illustrative summary analyses
  • Utilities analyses to support economic modelling in gastric cancer
  • Updates to a Health Impact Projection (HIP) model in gastric cancer

Glioblastoma

  • Development of a global value dossier in the treatment of glioblastoma
  • AMCP dossier in glioblastoma multiforme
  • Early global value dossier in newly diagnosed glioblastoma
  • Clinical trial analyses to support health-related quality of life (HRQoL) in glioblastoma
  • Review of instruments for a glioblastoma trial and recommendation of a strategy
  • PRO dossier on glioblastomas for the EMA
  • Literature review on overall survival and progression-free survival in glioblastomas
  • Poster on the association of HRQoL and NCF with progression-free survival (PFS) and PD in glioblastoma
  • Indirect comparison of two treatments in 2nd line glioblastoma
  • Training slide deck for COAs in glioblastoma

Head and neck cancer

  • Adaptation of a multi-indication value-based pricing model in head and neck cancer to China
  • Health economic advisory board on a treatment for head and neck cancer
  • Payer tools implementation guide in head & neck cancer
  • Payer value proposition deck in 2nd line head & neck cancer
  • Payer communications strategy and tools in head and neck cancer
  • Payer communication tool and summary in SCCHN
  • Burden of disease deck, payer value dossier deck and frequently asked questions deck in 2nd line head and neck cancer
  • One-pager on HPV in head and neck cancer
  • Market access and pricing tools to support a value proposition in squamous cell carcinoma of the head and neck (SCCHN)
  • Market access payer value tool in head and neck cancer
  • Economic value story in SCCHN
  • Standardization of economic models in head and neck cancer
  • Value-based model in head and neck cancer
  • Multi-indication budget impact model in head and neck cancer
  • Cost-effectiveness model in head and neck cancer
  • Global model update and country adaptations for a multi-indication value-based pricing (VBP) model on head and neck cancer
  • Dossier for a chemotherapy drug for head and neck cancer
  • Reimbursement dossiers in subgroups of head and neck cancer
  • Mini literature review in SCCHN
  • Literature review and payer communication tools in SCCHN
  • Development of an evidence compendium for HPV-related head and neck cancers
  • One-pager on HPV-related head and neck cancer
  • Update to a Belgian value-based pricing model in head and neck cancer
  • Updates to a Health Impact Projection (HIP) model in recurrent or metastatic head and neck cancer
  • Update of market access tools in SCCHN
  • Updates to a global value dossier from a targeted literature review in HPV-related head and neck cancer
  • Clinical trial analyses to support health-related quality of life in head and neck cancer
  • Qualitative interviews to assess equivalence of paper and electronically administered questionnaires in head and neck cancer
  • SMC submission of a chemotherapy drug in head and neck cancer
  • Two manuscripts and one mini report for the head and neck cancer models for the UK
  • US costing for a head and neck cancer model
  • Health-related quality of life analyses to support a treatment for head and neck cancer: a Q-TWiST analysis
  • AMNOG and ad hoc analyses to support health-related quality of life in SCCHN

Kidney cancer / Renal cell carcinoma

  • Landscape analysis for ablation in kidney cancer
  • Burden of disease deck in renal cell carcinoma
  • Market access payer value tool in renal cell carcinoma
  • Sensitivity analysis and budget impact model on renal cell carcinoma
  • Analyses of endpoints in oncology: Statistical analyses in renal cell carcinoma
  • Updates to a Health Impact Projection (HIP) model in locally advanced or metastatic renal cell carcinoma
  • Utilities analyses to support economic modelling in renal cell carcinoma
  • Value tool for decision making in renal cell carcinoma
  • e-v@luate platforms in renal cell carcinoma
  • Summary presentation of a workstream in renal disease
  • Caregiver burden in renal cell carcinoma in the EU
  • Scientific communication of a systematic literature review on caregiver burden in renal cell carcinoma
  • Budget impact model in renal cell carcinoma
  • Analyses of endpoints in oncology: Country-specific EQ-5D utilities in renal cell carcinoma
  • Clinical trial analyses to support health-related quality of life in renal cell carcinoma: Ad hoc analyses and Q&A document
  • Quick review of PRO measures for a phase II trial in renal cell carcinoma
  • General consultancy agreement to review two PRO measures in renal cell carcinoma to support labelling claims with the FDA and EMA

Leukaemia

  • Exploring physicians’ perceptions of adherence levels, reasons for non-adherence, and opinions of how to improve adherence in leukaemia patients receiving treatment
  • Patient satisfaction in chemotherapy for leukaemia

Acute lymphoblastic leukaemia

  • Support in IRB submissions and scientific dissemination in acute lymphoblastic leukaemia
  • Burden of refractory acute lymphoblastic leukaemia on patients and caregivers

Acute myeloid leukaemia (AML)

  • Global value dossier and e-v@luate platform for a treatment in AML
  • Global value dossier, conference poster and medical writing support in AML
  • Quality of life analysis in the treatment of AML
  • Payer evidence council value communication materials (booklet, slides and Q&A) to inform phase III trial design in AML
  • Cost-effectiveness analysis and budget impact analysis for a prognostic and minimal residual genetic tests for AML
  • Systematic literature review of healthcare resource utilisation in AML
  • Literature review of resource utilisation in AML
  • Strategic consulting on AML
  • Health-related quality of life in elderly patients with AML: Position paper on an AML treatment for inclusion in a value dossier
  • Qualitative research to understand the value of extended overall survival to AML patients

Chronic lymphocytic leukaemia (CLL)

  • Utility study in advanced CLL
  • Abstract and manuscript on utility study results in CLL
  • Payer evidence dossiers for treatments of CLL
  • Mixed treatment comparison and training meeting on a global value dossier for a treatment for CLL
  • Health state preference study mapping the change over the course of the CLL disease process
  • Conference poster on the health state preference study mapping the change over the course of the CLL disease process
  • Global value dossier for a treatment in CLL
  • Statistical analysis plans and provision of PRO support to the client for their trials of a biological therapy cancer treatment for CLL
  • General consultancy agreement to review PRO measures in CLL
  • Analysis of PRO data from the CLL registry
  • Manuscript on a budget impact model for a cross-indication biosimilar in CLL

Chronic myeloid leukaemia (CML)

  • Value dossier support in CML linking myelosuppression with quality of life impact
  • Value dossier support in CML linking response to utilities and additional analysis
  • Critical review of PRO instruments in CML
  • Adverse event to PRO linking in CML
  • Manuscript on AE-PRO linking in CML
  • Targeted literature review and manuscript on factors associated with adherence in CML
  • Development of a link between side effects and PROs in CML – a univariate approach

Liver cancer

  • Development of a HEOR strategy for treatment of hepatocellular cancer
  • Clinical trial analyses to support health-related quality of life in advanced hepatocellular carcinoma
  • Updates to a Health Impact Projection (HIP) model in hepatocellular carcinoma
  • Landscape analysis for ablation in liver cancer

Lung cancer

  • Preparation of 3 existing manuscripts on lung cancer for submission
  • Literature search and analysis of phase 2 vs phase 3 lung cancer studies
  • Literature and reimbursement review of intravenous versus subcutaneous therapies in lung cancer
  • Development of a pan-lung oncology treatment model
  • Landscape analysis for ablation in lung cancer
  • Patient interviews in lung cancer
  • Analyses of endpoints in oncology: Statistical analyses in lung cancer
  • Analyses of endpoints in oncology: Country-specific EQ-5D utilities in lung cancer
  • Analytical evidence for improvement in symptoms and quality of life in lung cancer patients on a specified treatment
  • Analytical evidence for improvement in symptoms and quality of life in pre and post-randomisation lung cancer patients (by age groups)
  • Strategic consulting, research and measurement in solid tumours
  • Strategic communications planning in lung cancer
  • Consulting for an FDA submission in lung cancer
  • Summary presentation of a workstream in lung cancer
  • Updates to a Health Impact Projection (HIP) model in extensive 1st line SCLC, locally advanced or metastatic 2nd line NSCLC, and metastatic 1st line NSCLC

Non-small cell lung cancer (NSCLC)

  • Global value dossier and e-v@luate platform in NSCLC
  • Global value dossier and e-v@luate platform in non-squamous NSCLC
  • Global value dossier and e-v@luate platform in advanced squamous NSCLC
  • Global value dossier for a treatment in metastatic NSCLC
  • Payer value deck and response to payer questions update in 1st line NSCLC
  • Updated payer value dossier deck and FAQs deck for 1st line NSCLC
  • Updated burden of disease decks, payer value dossier decks and FAQs decks for 1st line and 2nd line NSCLC
  • Societal costs, health-related quality of life systematic literature review and publications plan for NSCLC in Europe
  • Literature review of overall survival and bone metastases in NSCLC
  • Literature review to inform global market access materials in NSCLC
  • Structured literature review in advanced 1st line NSCLC
  • Systematic review and mixed treatment comparison in advanced NSCLC
  • Development of technical documentation and manuscript on NSCLC
  • Two manuscripts on the indirect comparison of the efficacy of two different therapies for NSCLC
  • Development of a manuscript on the cost-effectiveness of a treatment in NSCLC in Italy
  • Manuscript on the efficacy of three different drugs for the treatment of NSCLC
  • Model review of a drug used in the treatment of NSCLC
  • Multi-indication budget impact model in NSCLC
  • Adaptation of a multi-indication value-based pricing model in NSCLC to China
  • Value-based model in NSCLC
  • Update to a Belgian value-based pricing model in NSCLC
  • Standardisation of economic models in NSCLC
  • Global model update and country adaptations for a multi-indication value-based pricing (VBP) model on NSCLC
  • Burden of disease decks in advanced 1st line and 2nd line NSCLC
  • Burden of disease deck update in 1st line NSCLC
  • Integrated research plan in advanced melanoma and NSCLC
  • Value slide deck for treatment in NSCLC
  • Guidance documents for affiliates in treatment for NSCLC
  • Situational analysis report of epidermal growth factor receptor (EGFR) predictive testing in NSCLC
  • Communication toolkit for a lung cancer supplement
  • Companion diagnostics biomarker FAQs compilation deck in NSCLC
  • FAQs update in advanced 1st line NSCLC
  • FAQs deck update in 2nd line NSCLC
  • Payer slide decks and objection handler in NSCLC
  • Payer tools implementation guide in NSCLC
  • Payer value proposition deck update in 2nd line NSCLC
  • Payer value deck update in advanced 1st line NSCLC
  • Payer value deck and response to payer questions update in 1st line NSCLC
  • HTA submission support in epidermal growth factor receptor positive (EGFR+) and non-small cell lung cancer (NSCLC)
  • Value communication for a matching-adjusted indirect comparison (MAIC) in NSCLC
  • Abstract and manuscript on MAIC in NSCLC
  • Deep-dive trial design in NSCLC
  • Numerous abstracts and conference posters on NSCLC, advanced NSCLC and related treatments
  • Several abstracts and conference posters relating to the cost and cost effectiveness of a first-line treatment option for patients with NSCLC
  • Abstract and poster on progression-free survival and overall survival in patients with NSCLC
  • Literature review of outcomes and costs during treatment for advanced NSCLC
  • Literature review and consultancy on NSCLC
  • Manuscript on stage IIIb and IV NSCLC
  • Development of a measurement dossier in advanced NSCLC for the EMA
  • Meta-analysis and manuscript on stage IIIb and IV NSCLC
  • Development of posters for a MAIC in advanced NSCLC
  • Epidemiology evidence, patient pathway modelling and literature review in advanced NSCLC
  • Statistical analyses of clinical trial data (safety study) in NSCLC
  • Statistical analyses of clinical trial data (observational study) in NSCLC
  • Clinical trial analyses to support health-related quality of life in first-line NSCLC
  • Qualitative study on the needs and preferences of patients with advanced NSCLC for maintenance therapy
  • Development of an analysis plan in NSCLC for the USA and Europe
  • Analysis of PRO data in NSCLC
  • Qualitative interviews to understand the impact of NSCLC on quality of life and on caregivers and family members
  • EQ-5D review for an EMA measurement dossier in advanced NSCLC
  • Exploratory qualitative interviews in NSCLC patients to assess progression-free survival
  • Comparative effectiveness of two treatments for the treatment of NSCLC
  • Feasibility network meta-analysis comparison of two treatments for NSCLC
  • Exploratory analysis of the Visual Symptom Assessment Questionnaire (VSAQ) in patients who have undergone treatment for NSCLC
  • Utilities analyses to support economic modelling in NSCLC
  • Clinical trial analyses to support health-related quality of life in NSCLC
  • Impact of whole brain radiation therapy in patients with NSCLC with brain metastases

Small cell lung cancer (SCLC)

  • Global value dossier and upload to e-v@luate platform in SCLC
  • AMCP dossier in SCLC
  • Systematic literature reviews for the societal and health-related quality of life burden of SCLC
  • Systematic literature review and manuscript on real-world effectiveness and tolerability of treatments in SCLC
  • Literature review on real-world effectiveness and tolerability of treatment in SCLC
  • Utility study in SCLC
  • Development of a budget impact model in SCLC
  • Budget impact model in 1st line SCLC
  • Development of a disease conceptual model and endpoint recommendation for SCLC
  • Phase IV clinical trial analysis of two drugs used in the treatment of SCLC
  • Analysis of symptoms for a drug used to treat SCLC
  • Full text reports on the longitudinal analyses of a drug used to treat SCLC for EU submission
  • Literature and PRO strategy for SCLC
  • Clinical trial analyses to support health-related quality of life in SCLC
  • Literature review and consultancy on SCLC

Lymphomas

B-cell lymphoma

  • Payer evidence dossiers in B-Cell lymphoma
  • Development of a budget impact model for primary mediastinal B-cell lymphoma (PMBCL)
  • Literature review and preparation of a PRO strategy in large B-cell lymphoma
  • Burden of diffuse large B-cell lymphoma on patients and caregivers
  • e-v@luate platform in diffuse large B-cell lymphoma

Hodgkin’s lymphoma

  • Payer evidence dossiers in non-Hodgkin’s lymphoma
  • Early payer engagement deck in classical Hodgkin’s lymphoma
  • Analyses of endpoints in oncology: Statistical analyses in Hodgkin’s lymphoma
  • Clinical trial analyses to support health-related quality of life in Hodgkin’s lymphoma

Non-Hodgkin’s lymphoma

  • Update of a payer evidence dossier in non-Hodgkin’s lymphoma
  • Literature review and conceptual mapping in non-Hodgkin’s lymphoma
  • Strategic PRO endpoint support, gap analysis and patient interviews in a biological therapy treatment for non-Hodgkin’s lymphoma
  • Validation of a patient satisfaction questionnaire in non-Hodgkin’s lymphoma
  • Conference poster and slide deck on non-Hodgkin’s lymphoma
  • Manuscript on a budget impact model for a cross-indication biosimilar in diffuse large B-Cell lymphoma, follicular lymphoma, follicular non-Hodgkin’s lymphoma

Lymphomas (other)

  • Core value dossier and value proposition in cutaneous T-cell lymphoma
  • Development of a budget impact tool for a treatment for chronic lymphatic lymphoma for Spain
  • Support programme for reimbursement submissions in cutaneous T-cell lymphoma
  • Strategic consulting for a lymphoma trial
  • Clinical trial analysis of health-related quality of life data in patients with previously untreated follicular lymphoma
  • Manuscript on a budget impact model for a cross-indication biosimilar in diffuse large B-Cell lymphoma, follicular lymphoma, and follicular non-Hodgkin’s lymphoma

Melanoma

  • Adaptation of a multi-indication value-based pricing model in melanoma to China
  • Literature review in metastatic melanoma treatment patterns
  • Scientific communication of a systematic literature review on caregiver burden in advanced metastatic melanoma
  • Global value dossier for a treatment in melanoma
  • Development of global market access materials (disease burden slide deck, payer value story and FAQs) in metastatic melanoma to support local access teams
  • Payer slide decks and objection handler update in metastatic melanoma
  • Implementation guide in metastatic melanoma
  • Burden of disease deck update in ipi refractory and ipi naïve advanced melanoma
  • Payer value proposition deck update in ipi refractory advanced melanoma
  • Payer value proposition deck update in ipi naïve advanced melanoma
  • Updated implementation guide in melanoma
  • Frequently asked questions deck in ipi refractory and ipi naïve advanced melanoma
  • Updated burden of disease deck, payer value dossier decks and obstacle handler in a treatment for refractory & naïve melanoma
  • Development of a budget impact model for adjuvant melanoma
  • KOL interviews and primary research into treatment patterns in adjuvant melanoma
  • Payer value deck and response to payer questions in adjuvant melanoma
  • Payer value deck and response to payer questions update in advanced melanoma
  • Burden of disease deck in adjuvant melanoma
  • Burden of disease and payer value deck in adjuvant and advanced melanoma
  • Standardization of economic models in melanoma
  • Value-based model in melanoma
  • Multi-indication budget impact model in melanoma
  • Global model update and country adaptations for a multi-indication value-based pricing (VBP) model on melanoma
  • Adaptation of a value-based pricing multi-indication global model in oncology to Greece
  • Strategic communications planning in melanoma
  • Update to a Belgian value-based pricing model in melanoma
  • Updates to a Health Impact Projection (HIP) model in adjuvant melanoma and unresectable or metastatic melanoma
  • Preparation of a genomics methods paper in melanoma
  • Summary presentation of a workstream in melanoma
  • Caregiver burden in advanced melanoma
  • Caregiver burden in melanoma in the EU
  • Evidence synthesis on the comparative effectiveness of systemic therapies for unresectable stage IIIc and stage IV melanoma
  • Pilot patient interviews in melanoma
  • Exploratory analyses of endpoints in oncology: Statistical analyses in melanoma
  • Analyses of endpoints in oncology: Statistical analyses in first-line melanoma
  • Clinical trial analyses to support the relationship between adverse events and health-related quality of life, health status and work productivity in melanoma
  • Clinical trial analyses to support health-related quality of life in melanoma: AMNOG analyses for combination arm therapy
  • Network meta-analysis on the efficacy of first line treatment for unresectable stage IIIC/IV melanoma
  • AMNOG analyses to support health-related quality of life in melanoma